Editing Antiandrogen (section)

====Acne====
Systemic antiandrogens are generally not used to treat acne in males due to their high risk of feminization (e.g., gynecomastia) and sexual dysfunction.<ref name="PlewigKligman2012">{{cite book| vauthors = Plewig G, Kligman AM |title= ACNE and ROSACEA|url=https://books.google.com/books?id=0cD-CAAAQBAJ&pg=PA687|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-59715-2|pages=687–}}</ref><ref name="AlldredgeCorelli2012">{{cite book| vauthors = Alldredge BK, Corelli RL, Ernst ME |title=Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs|url=https://books.google.com/books?id=qcVpuHngXK0C&pg=PA952|date=1 February 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-713-7|pages=952–}}</ref> However, they have been studied for acne in males and found to be effective.<ref name="WardBrogden1984">{{cite journal | vauthors = Ward A, Brogden RN, Heel RC, Speight TM, Avery GS | title = Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders | journal = Drugs | volume = 28 | issue = 1 | pages = 6–37 | date = July 1984 | pmid = 6235105 | doi = 10.2165/00003495-198428010-00002 }}</ref><ref name="Rasmusson1986">{{cite book| vauthors = Rasmusson GH |title= Chapter 18. Chemical Control of Androgen Action|volume=21|year=1986|pages=179–188|issn=0065-7743|doi=10.1016/S0065-7743(08)61128-8|series=Annual Reports in Medicinal Chemistry|publisher= Academic Press|isbn=9780120405213}}</ref><ref name="Cormanevan der Meeren1981">{{cite journal| vauthors = Cormane RH, van der Meeren HL |title=Cyproteronacetate in the management of severe acne in males|journal=Archives of Dermatological Research |volume=271 |issue=2 |year=1981 |pages=183–187 |issn=0340-3696|doi=10.1007/BF00412545|s2cid=12153042}}</ref><ref name="pmid2945742">{{cite journal | vauthors = Misch KJ, Dolman WF, Neild V, Rhodes EL | title = Response of male acne to antiandrogen therapy with cyproterone acetate | journal = Dermatologica | volume = 173 | issue = 3 | pages = 139–142 | date = 1986 | pmid = 2945742 | doi = 10.1159/000249236 }}</ref> [[Clascoterone]], a topical antiandrogen, is effective for acne in males, albeit modestly,<ref name="BasendwhAlharbiBukhamsin2024" /> and has been approved by the FDA in August 2020.<ref name="pmid31487336">{{cite journal | vauthors = Kircik LH | title = What's new in the management of acne vulgaris | journal = Cutis | volume = 104 | issue = 1 | pages = 48–52 | date = July 2019 | pmid = 31487336 | url = https://www.mdedge.com/dermatology/article/204308/acne/whats-new-management-acne-vulgaris | access-date = 2020-03-30 | archive-date = 2020-10-26 | archive-url = https://web.archive.org/web/20201026050003/https://www.mdedge.com/dermatology/article/204308/acne/whats-new-management-acne-vulgaris | url-status = live }}</ref><ref name="pmid27416311">{{cite journal | vauthors = Hassoun LA, Chahal DS, Sivamani RK, Larsen LN | title = The use of hormonal agents in the treatment of acne | journal = Seminars in Cutaneous Medicine and Surgery | volume = 35 | issue = 2 | pages = 68–73 | date = June 2016 | pmid = 27416311 | doi = 10.12788/j.sder.2016.027 | doi-broken-date = 1 November 2024 }}</ref><ref>{{Cite web |date=2020-08-28 |title=Cassiopea Receives FDA Approval for Winlevi® (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor - Cassiopea |url=https://www.cassiopea.com/2020/08/27/cassiopea-receives-fda-approval-for-winlevi-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor/ |access-date=2024-04-15 |archive-url=https://web.archive.org/web/20200828021558/https://www.cassiopea.com/2020/08/27/cassiopea-receives-fda-approval-for-winlevi-clascoterone-cream-1-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor/ |archive-date=2020-08-28 }}</ref><ref>{{Cite web |title=Drugs@FDA: FDA-Approved Drugs |url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213433 |access-date=2024-04-15 |website=www.accessdata.fda.gov |language=en}}</ref>